ArticleEuropean journal of nuclear medicine and molecular imaging2026
An interpretable machine learning model integrating [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPerforation following chemotherapy in gastrointestinal lymphoma (PFCGL) is a rare but severe and life-threatening complication. Early pre-chemotherapy prediction is crucial for optimizing treatment and improving outcomes, yet it remains challenging. This study aimed to develop a machine learning (ML) model combining clinical features and [ MATERIALS AND
methodsA total of 257 patients diagnosed at two hospitals with gastrointestinal lymphoma were included. Clinical data and PET/CT images were collected. PET/CT radiomics signature were extracted from the FDG-avid regions. Five ML algorithms were used to develop predictive models, including clinical, PET/CT radiomics, and clinical-PET/CT models. The SHapley Additive exPlanations (SHAP) method was applied for model interpretability.
resultsThe internal training, internal validation and external validation cohorts consisted of 144 patients (mean age: 56.90 ± 14.69 years; 88 males), 63 patients (mean age: 61.76 ± 13.71 years; 36 males) and 50 patients (mean age: 63.28 ± 12.17 years; 27 males), respectively. Among these, 22, 11, and 11 patients were diagnosed with PFCGL in the three cohorts, correspondingly. For clinical features, elevated C-reactive protein levels and pathological type of T-cell non-Hodgkin's lymphoma were risk factors for predicting PFCGL. SHAP analysis revealed that PET/CT radiomics signature significantly contributed to the prediction of PFCGL. The clinical-PET/CT model utilizing the logistic regression (LR) algorithm exhibited superior predictive performance for PFCGL compared to the individual clinical model and the PET/CT radiomics model employing the ExtraTrees algorithm. This was evidenced by the area under the curve (AUC) values of 0.918, 0.872 and 0.857 in the training cohort, 0.858, 0.795 and 0.849 in the internal validation cohort, and 0.852, 0.770 and 0.807 in the external validation cohort, respectively.
conclusionThe combined model that integrates [
Indexed as
Identifiers
42151619What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.